These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39121538)

  • 21. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
    Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
    BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Kosti O; Xu X; Veenstra TD; Hsing AW; Chu LW; Goldman L; Bebu I; Collins S; Dritschilo A; Lynch JH; Goldman R
    Prostate; 2011 Apr; 71(5):507-16. PubMed ID: 20886539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases.
    Nithipatikom K; Isbell MA; See WA; Campbell WB
    Cancer Lett; 2006 Feb; 233(2):219-25. PubMed ID: 15882928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
    Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
    Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum 25-hydroxy vitamin D levels in Bulgarian patients with prostate cancer: a pilot study.
    Galunska B; Gerova D; Kosev P; Anakievski D; Hinev A
    Clin Lab; 2015; 61(3-4):329-35. PubMed ID: 25975000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
    Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
    J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment.
    Jayapalan JJ; Ng KL; Shuib AS; Razack AH; Hashim OH
    Electrophoresis; 2013 Jun; 34(11):1663-9. PubMed ID: 23417432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of urine-circulating miRNAs for detection of prostate cancer.
    Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
    Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
    Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
    Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
    Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.
    Gao Q; Su X; Annabi MH; Schreiter BR; Prince T; Ackerman A; Morgas S; Mata V; Williams H; Lee WY
    Clin Genitourin Cancer; 2019 Jun; 17(3):183-190. PubMed ID: 30853355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of ferritin with prostate cancer.
    Su Q; Lei T; Zhang M
    J BUON; 2017; 22(3):766-770. PubMed ID: 28730787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
    Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
    Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study.
    Dereziński P; Klupczynska A; Sawicki W; Pałka JA; Kokot ZJ
    Int J Med Sci; 2017; 14(1):1-12. PubMed ID: 28138303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
    Ma W; Diep K; Fritsche HA; Shore N; Albitar M
    Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.